Cancer is now the #1 catastrophic claim for self-funded health care plansWe have a plan to reduce your costs by improving your care
StageZero's programs can help reduce your company's healthcare costs by more than 50% through early interventions.
|
The following case-study demonstrates a 58% reduction in breast cancer costs alone through early interventionPresumptions
Predicted Financial Benefit
A Cost Avoidance of $3,446,685
|
|
Contact us to learn more
|
Our Process is Our Difference
StageZero provides advanced diagnostics that can not only identify cancer earlier among employees, but also identify the early warning signs that can lead to a future cancer diagnosis. This paired with a physician supervised intervention program run by experienced oncologists can reduce costs for your organization dramatically.
Our Programs Enhance Your Benefits
ARISTOTLE®
|
AVRT™
|
|
|
Our MissionToday the field of cancer research and discovery is focused on the "Moonshot" - a cure for cancer. But at StageZero Life Sciences we believe in "groundshots" too by doing whatever we can to help improve outcomes through cancer prevention, earlier cancer detection and adjunctive cancer therapy to improve cancer outcomes.
|
Our LaboratoryStageZero Life Sciences U.S. Headquarters is based in Richmond, VA. Our laboratory in Richmond is registered and certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the U.S. College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care.
|
References
1. https://www.cancer.gov/types/breast/risk-fact-sheet
2.https://www.cdc.gov/nchs/hus/topics/mammography.html
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6 American
4. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
6.GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567.
Headline on catastrophic cancer claims: 2022 Sun Life Stop-Loss Research Report: High-cost Claims and Injectable Drug Trends Analysis.
Aristotle™ was developed, and its performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration.
1. https://www.cancer.gov/types/breast/risk-fact-sheet
2.https://www.cdc.gov/nchs/hus/topics/mammography.html
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6 American
4. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
6.GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567.
Headline on catastrophic cancer claims: 2022 Sun Life Stop-Loss Research Report: High-cost Claims and Injectable Drug Trends Analysis.
Aristotle™ was developed, and its performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration.